Informed decisions will improve the way cancer is treated. On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Our platform will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival.
Products currently in development are based on two core technologies: 1) DNA repair biomarkers that predict treatment response and 2) Microfluidic chip technology that enables capture, enumeration and characterization of circulating tumor cells (CTCs) in the bloodstream.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 12/01/09 | Series A | 26M | Unknown |
People
Mara Aspinall (President, CEO)
Competitors
BioCancell Therapeutics:
BioCancell Therapeutics Inc. is a biotechnology company specializing in the development of Patient-Oriented, Targeted Therapy for… See Company Profile »
NeoDiagnostix:
NeoDiagnostix was founded to develop and provide cancer diagnostic testing services using genetic technologies. The Company… See Company Profile »
Exagen Diagnostics:
eXagen DIAGNOSTICS, Inc.™ is a leader in the discovery, development and delivery of genomic marker tests… See Company Profile »
CellPoint Diagnostics:
CellPoint Diagnostics is an early stage company developing diagnostic, monitoring, and molecular analytical tools for cancer.… See Company Profile »